Oral News and Research

RSS

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Ardea Biosciences, Inc. announced positive results from the first dosing group of an ongoing drug-drug interaction and pharmacodynamic study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). This

1 Dec 2009

Chinese SFDA approves Tianyin Pharmaceutical's Pediatric Fever and Cough Oral Liquid

Tianyin Pharmaceutical Co., Inc.,, a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has received approvals from the Chinese State Food and Drug Administration (SFDA) to produce Pediatric Fever and Cough Oral Liquid in dosage form of 10 ml/tube (SFDA approval number Z20093060) and Antibacterial and Anti-inflammatory Capsules in dosage form of 0.27 gram/capsule (SFDA approval number Z20090855).

1 Dec 2009

Health care reform bill will disrupt dental coverage of more than 441,000 Virginia children

Health care reform legislation passed by the House of Representatives threatens unintended consequences that would disrupt dental coverage for more than 441,000 Virginia children, limit competition for dental benefits, and disrupt many dentist-patient relationships, according to George Levicki, DDS, president and CEO of Delta Dental of Virginia.

1 Dec 2009

Women with gestational glucose intolerance at risk of metabolic syndrome

Women who have gestational glucose intolerance (a condition less severe than gestational diabetes) exhibit multiple cardiovascular risk factors as early as three months after birth, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

1 Dec 2009

Refuse to file letter on NDA for Cladribine Tablets issued to EMD Serono

EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS).

1 Dec 2009

Avioq receives premarket approval from FDA for Avioq HIV-1 Microelisa System

Avioq, Inc. announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the Avioq HIV-1 Microelisa System.

1 Dec 2009

CCII capsules offer safe and effective treatment for rheumatoid arthritis

Chicken collagen can provide relief from rheumatoid arthritis (RA) symptoms. A randomised, controlled trial, published in BioMed Central's open access journal Arthritis Research & Therapy, has found that Chicken type II collagen (CCII), a protein extracted from the cartilage of chicken breast, is a safe and effective treatment for RA.

1 Dec 2009

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

1 Dec 2009

Home visits to educate children with asthma can lead to fewer flare-ups and less frequent trips to ER

A few home visits by a health care specialist to educate children with asthma about basic strategies for earlier symptom recognition and improving medication use can lead to fewer flare-ups and less frequent trips to the ER, according to research from Johns Hopkins Children's Center published in the December issue of Pediatrics.

1 Dec 2009

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.

30 Nov 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Raleigh dentist to educate public about the benefits of sedation dental care

Raleigh dentist Robert L. Williamson III, DDS and Associates have launched a new plan to educate the community and patients about sedation dentistry and its many benefits.

30 Nov 2009

Study on deaths from cancer in Europe shows steady decline in mortality

New figures on deaths from cancer in Europe show a steady decline in mortality between the periods 1990-1994 and 2000-2004. Deaths from all cancers in the European Union (EU) between these two periods fell by nine percent in men and eight percent in women, with a large drop among the middle-aged population.

29 Nov 2009

Advitech announces merger operations with Botaneco Specialty Ingredients

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that, further to the consolidation of its common shares on a 8-for-1 basis (the "Consolidation"), the TSX Venture Exchange Inc. (the "TSX-V") has approved the release from escrow of the previously announced acquisition of all the issued and outstanding shares of Botaneco Specialty Ingredients Inc.

27 Nov 2009

Research shows rare parasitic disease is transmitted by gay men

A rare parasitic disease, which normally only is transmitted by contaminated water, has been shown to be transmitted by gay sex between hiv-positive men. In the industrial world the disease is virtually absent, but from now on that could change.

27 Nov 2009

Simulations Plus launches new version of GastroPlus

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announces the release of GastroPlus Version 6.1, the latest version of its state-of-the-art software used by pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

Congress brings oral health into conversation to improve nation's overall health

The W.K. Kellogg Foundation commends Congress for its recognition of the urgent need to comprehensively and substantially strengthen oral health care for our most vulnerable children.

25 Nov 2009

Oral News and Research

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Chinese SFDA approves Tianyin Pharmaceutical's Pediatric Fever and Cough Oral Liquid

Health care reform bill will disrupt dental coverage of more than 441,000 Virginia children

Women with gestational glucose intolerance at risk of metabolic syndrome

Refuse to file letter on NDA for Cladribine Tablets issued to EMD Serono

Avioq receives premarket approval from FDA for Avioq HIV-1 Microelisa System

CCII capsules offer safe and effective treatment for rheumatoid arthritis

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

Home visits to educate children with asthma can lead to fewer flare-ups and less frequent trips to ER

NanoViricides announces filing of its quarterly report with the SEC

Micromet to present new results from its blinatumomab study at the ASH meeting

Gentium announces financial results for the third quarter ended September 30, 2009

Raleigh dentist to educate public about the benefits of sedation dental care

Study on deaths from cancer in Europe shows steady decline in mortality

Advitech announces merger operations with Botaneco Specialty Ingredients

Research shows rare parasitic disease is transmitted by gay men

Simulations Plus launches new version of GastroPlus

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Congress brings oral health into conversation to improve nation's overall health

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News